ArriVent says furmonertinib missed its main goal in a late-stage lung cancer study
Median progression-free survival was 11 months at the highest dose versus 9.5 months on chemotherapy, a difference that missed statistical significance.
Median progression-free survival was 11 months at the highest dose versus 9.5 months on chemotherapy, a difference that missed statistical significance.